Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: Evidence that miR200a-3p is regulated by O6-methylguanine methyltransferase and promotes temozolomide responsiveness

Cancer Biology and Therapy

Volumn 15, Issue 7, 2014, Pages 938-950

  Berthois, Yolande ^a   Delfino, Christine ^a   Metellus, Philippe ^a,b   Fina, Frederic ^c   Nanni Metellus, Isabelle ^c   Al Aswy, Hayat ^a   Pirisi, Victor ^a   Ouafik, L'Houcine ^a,c   Boudouresque, Françoise ^a  

^a University of the Mediterranean Aix Marseille II   (France)

^b TIMONE HOSPITAL   (France)

^c HÔPITAL NORD   (France)

Author keywords

Chemoresistance; Glioblastoma; MicroRNA; MiR 200a 3p; MiR21; Temozolomide

Indexed keywords

CARMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA 200A; MICRORNA 21; TEMOZOLOMIDE; VINCRISTINE; ALKYLATING AGENT; DACARBAZINE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; MICRORNA; MIRN200 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER INHIBITION; CELL PROLIFERATION; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GLIAL CELL CULTURE; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLIOMA; GLIOMA CELL LINE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PRIMARY CULTURE; TUMOR GROWTH; UPREGULATION; VERY ELDERLY; ANALOGS AND DERIVATIVES; BRAIN TUMOR; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84903848549     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28920     Document Type: Article

References (68)

1. Tate MC, Aghi MK. Biology of angiogenesis and invasion in glioma. Neurotherapeutics 2009; 6:447-57; PMID:19560735; http://dx.doi.org/10.1016/j. nurt.2009.04.001
2. Bauchet L, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, Pallusseau L, Carnin C, Lainé K, Schlama A, et al.; Société Française de Neurochirurgie (SFNC); Club de Neuro-Oncologie of the Société Française de Neurochirurgie (CNOSFNC); Société Française de Neuropathologie (SFNP); Association des Neuro-Oncologues d'Expression Française (ANOCEF). Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol 2010; 12:725-35; PMID:20364023; http://dx.doi.org/10.1093/neuonc/noq030
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459-66; PMID:19269895; http://dx.doi.org/10.1016/S1470-2045(09)70025-7
4. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 2002; 8:2725-34; PMID:12171906 (Pubitemid 34856362)
5. Oliva CR, Nozell SE, Diers A, McClugage SG 3rd, Sarkaria JN, Markert JM, Darley-Usmar VM, Bailey SM, Gillespie GY, Landar A, et al. Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem 2010; 285:39759-67; PMID:20870728; http://dx.doi.org/10.1074/jbc.M110.147504
6. Le Calvé B, Rynkowski M, Le Mercier M, Bruyère C, Lonez C, Gras T, Haibe-Kains B, Bontempi G, Decaestecker C, Ruysschaert JM, et al. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia 2010; 12:727-39; PMID:20824049
7. van Nifterik KA, van den Berg J, van der Meide WF, Ameziane N, Wedekind LE, Steenbergen RD, Leenstra S, Lafleur MV, Slotman BJ, Stalpers LJ, et al. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br J Cancer 2010; 103:29-35; PMID:20517307; http://dx.doi.org/10.1038/sj.bjc.6605712
8. Spiegl-Kreinecker S, Pirker C, Filipits M, Lötsch D, Buchroithner J, Pichler J, Silye R, Weis S, Micksche M, Fischer J, et al. O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro Oncol 2010; 12:28-36; PMID:20150365; http://dx.doi.org/10.1093/neuonc/nop003
9. Chinot OL, Barrié M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 2007; 25:1470-5; PMID:17442989; http://dx.doi.org/10.1200/JCO.2006.07.4807 (Pubitemid 46733073)
10. Gaspar N, Marshall L, Perryman L, Bax DA, Little SE, Viana-Pereira M, Sharp SY, Vassal G, Pearson AD, Reis RM, et al. MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res 2010; 70:9243-52; PMID:20935218; http://dx.doi.org/10.1158/0008-5472.CAN-10-1250
11. Bobola MS, Kolstoe DD, Blank A, Silber Jr. Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression. Mol Cancer Ther 2010; 9:1208-18; PMID:20457618; http://dx.doi.org/10.1158/1535-7163.MCT-10-0010
12. Zhang J, Stevens MF, Laughton CA, Madhusudan S, Bradshaw TD. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology 2010; 78:103-14; PMID:20357518; http://dx.doi.org/10.1159/000306139
13. Jiang Z, Pore N, Cerniglia GJ, Mick R, Georgescu MM, Bernhard EJ, Hahn SM, Gupta AK, Maity A. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 2007; 67:4467-73; PMID:17483362; http://dx.doi.org/10.1158/0008-5472.CAN-06-3398 (Pubitemid 46815097)
14. Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wang J, et al. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomideinduced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. Endocrinology 2013; 154:1247-59; PMID:23384836; http://dx.doi.org/10.1210/en.2012-1908
15. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007; 13:2038-45; PMID:17404084; http://dx.doi.org/10.1158/1078-0432.CCR-06-2149 (Pubitemid 46649870)
16. Happold C, Roth P, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G, Weller M. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem 2012; 122:444-55; PMID:22564186; http://dx.doi.org/10.1111/j.1471-4159.2012.07781.x
17. Blough MD, Beauchamp DC, Westgate MR, Kelly JJ, Cairncross JG. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma. J Neurooncol 2011; 102:1-7; PMID:20593219; http://dx.doi.org/10.1007/s11060-010-0283-9
18. Chen CH, Chang YJ, Ku MSB, Chung KT, Yang JT. Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation. J Mol Med (Berl) 2011; 89:303-15; PMID:21340685; http://dx.doi.org/10.1007/s00109-010-0707-1
19. Momota H, Nerio E, Holland EC. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 2005; 65:7429-35; PMID:16103096; http://dx.doi.org/10.1158/0008-5472.CAN-05-1042 (Pubitemid 41161277)
20. Zhang W, Zhang J, Yan W, You G, Bao Z, Li S, Kang C, Jiang C, You Y, Zhang Y, et al. Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer 2013; 119:814-24; PMID:22990979; http://dx.doi.org/10.1002/cncr.27826
21. Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005; 334:1351-8; PMID:16039986; http://dx.doi.org/10.1016/j.bbrc.2005.07.030 (Pubitemid 41074723)
22. Niyazi M, Zehentmayr F, Niemöller OM, Eigenbrod S, Kretzschmar H, Schulze-Osthoff K, Tonn JC, Atkinson M, Mörtl S, Belka C. MiRNA expression patterns predict survival in glioblastoma. Radiat Oncol 2011; 6:153-61; PMID:22074483; http://dx.doi.org/10.1186/1748-717X-6-153
23. Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta 2010; 1803:1231-43; PMID:20619301; http://dx.doi.org/10.1016/j.bbamcr.2010.06.013
24. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302:1-12; PMID:16989803; http://dx.doi.org/10.1016/ j.ydbio.2006.08.028 (Pubitemid 46096921)
25. DeSano JT, Xu L. MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J 2009; 11:682-92; PMID:19842044; http://dx.doi.org/10.1208/ s12248-009-9147-7
26. Hernando E. microRNAs and cancer: role in tumorigenesis, patient classification and therapy. Clin Transl Oncol 2007; 9:155-60; PMID:17403626; http://dx.doi.org/10.1007/s12094-007-0029-0
27. Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumorsuppressive pathways in glioblastoma cells. Cancer Res 2008; 68:8164-72; PMID:18829576; http://dx.doi.org/10.1158/0008-5472.CAN-08-1305
28. Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S, Angileri FF, Maio F, Cama A, Germanò A, Vita G, et al. miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol 2009; 93:325-32; PMID:19159078; http://dx.doi.org/10.1007/s11060-009-9797-4
29. Hermansen SK, Dahlrot RH, Nielsen BS, Hansen S, Kristensen BW. MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. J Neurooncol 2013; 111:71-81; PMID:23104517; http://dx.doi.org/10.1007/ s11060-012-0992-3
30. Lakomy R, Sana J, Hankeova S, Fadrus P, Kren L, Lzicarova E, Svoboda M, Dolezelova H, Smrcka M, Vyzula R, et al. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci 2011; 102:2186-90; PMID:21895872; http://dx.doi.org/10.1111/j.1349-7006.2011.02092.x
31. Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010; 116:945-52; PMID:20393129; http://dx.doi.org/10.1182/blood-2010-01-263889
32. Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, Shu Y. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010; 64:399-408; PMID:20363096; http://dx.doi.org/10.1016/j.biopha.2010.01.018
33. Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010; 5:e10630; PMID:20498843; http://dx.doi.org/10.1371/journal.pone.0010630
34. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9:582-9; PMID:18483486; http://dx.doi.org/10.1038/embor.2008.74 (Pubitemid 351772923)
35. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10:593-601; PMID:18376396; http://dx.doi.org/10.1038/ncb1722 (Pubitemid 351627379)
36. Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo A, de Santiago J, Robledo M, et al. The miR-200 family controls β-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 2011; 18:85-95; PMID:21051560; http://dx.doi.org/10.1677/ERC-10-0148
37. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138:592-603; PMID:19665978; http://dx.doi.org/10.1016/j.cell.2009.07.011
38. Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS, Borre M, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011; 128:1327-34; PMID:20473948; http://dx.doi.org/10.1002/ijc.25461
39. Li Y, VandenBoom TG, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabineresistant pancreatic cancer cells. Cancer Res 2009; 69:6704-12; PMID:19654291; http://dx.doi.org/10.1158/ 0008-5472.CAN-09-1298
40. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, et al. miR-200 expression regulates epithelialto-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009; 15:5060-72; PMID:19671845; http://dx.doi.org/10.1158/1078-0432.CCR-08-2245
41. Mueller DW, Rehli M, Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol 2009; 129:1740-51; PMID:19212343; http://dx.doi.org/10.1038/jid.2008.452
42. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 2008; 18:549-57; PMID:18379589; http://dx.doi.org/10.1038/cr.2008.45 (Pubitemid 351630945)
43. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67:8699-707; PMID:17875710; http://dx.doi.org/10.1158/ 0008-5472.CAN-07-1936 (Pubitemid 47437445)
44. Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, Kornmann M, Ju J. Prognostic values of microRNAs in colorectal cancer. Biomark Insights 2006; 2:113-21; PMID:18079988
45. Saydam O, Shen Y, Würdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, et al. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol 2009; 29:5923-40; PMID:19703993; http://dx.doi.org/10.1128/MCB.00332-09
46. Hayashi T, Adachi K, Ohba S, Hirose Y. The Cdk inhibitor flavopiridol enhances temozolomideinduced cytotoxicity in human glioma cells. J Neurooncol 2013; 115:169-78; PMID:23943501; http://dx.doi.org/10.1007/s11060-013-1220-5
47. Shen W, Hu J-A, Zheng J-S. Mechanism of temozolomide-induced antitumour effects on glioma cells. J Int Med Res 2014; 42:164-72; PMID:24326954; http://dx.doi.org/10.1177/0300060513501753
48. Filippi-Chiela EC, Thomé MP, Bueno e Silva MM, Pelegrini AL, Ledur PF, Garicochea B, Zamin LL, Lenz G. Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomideinduced senescence in glioma cells. BMC Cancer 2013; 13:147-56; PMID:23522185; http://dx.doi.org/10.1186/1471-2407-13-147
49. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, Taylor J, Hanash SM. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 2001; 61:6885-91; PMID:11559565 (Pubitemid 32896514)
50. van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS, Sommer C, Reifenberger G, Hanash SM. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and realtime reverse transcription-polymerase chain reaction. Am J Pathol 2003; 163:1033-43; PMID:12937144; http://dx.doi.org/10. 1016/S0002-9440(10)63463-3 (Pubitemid 37040139)
51. Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R, Kerin MJ. Systemic mirnas as potential biomarkers for malignancy. Int J Cancer 2012; 131:2215-22; PMID:22618667; http://dx.doi.org/10.1002/ijc.27642
52. Nair VS, Maeda LS, Ioannidis JP. Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst 2012; 104:528-40; PMID:22395642; http://dx.doi.org/10.1093/jnci/djs027
53. Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y. Interactions of miR-323/miR-329 and miR-130a/miR155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med 2013; 11:10; PMID:23281771; http://dx.doi.org/10.1186/1479-5876-11-10
54. Fu J, Rodova M, Nanta R, Meeker D, Van Veldhuizen PJ, Srivastava RK, Shankar S. NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200. Neuro Oncol 2013; 15:691-706; PMID:23482671; http://dx.doi.org/10. 1093/neuonc/not011
55. Metellus P, Coulibaly B, Nanni I, Fina F, Eudes N, Giorgi R, Barrie M, Chinot O, Fuentes S, Dufour H, et al. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation. Cancer 2009; 115:4783-94; PMID:19637364; http://dx.doi.org/10.1002/cncr.24546
56. Haenisch S, Cascorbi I. miRNAs as mediators of drug resistance. Epigenomics 2012; 4:369-81; PMID:22920178; http://dx.doi.org/10.2217/epi.12.39
57. Ren Y, Zhou X, Mei M, Yuan XB, Han L, Wang GX, Jia ZF, Xu P, Pu PY, Kang CS. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTENmutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 2010; 10:27-34; PMID:20113523; http://dx.doi.org/10.1186/1471-2407-10-27
58. Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res 2007; 67:8994-9000; PMID:17908999; http://dx.doi.org/10.1158/0008- 5472.CAN-07-1045 (Pubitemid 47535880)
59. Shi L, Chen J, Yang J, Pan T, Zhang S, Wang Z. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 2010; 1352:255-64; PMID:20633539; http://dx.doi.org/10.1016/j.brainres.2010.07.009
60. Li Y, Zhao S, Zhen Y, Li Q, Teng L, Asai A, Kawamoto K. A miR-21 inhibitor enhances apoptosis and reduces G(2)-M accumulation induced by ionizing radiation in human glioblastoma U251 cells. Brain Tumor Pathol 2011; 28:209-14; PMID:21618027; http://dx.doi.org/10.1007/s10014-011-0037-1
61. Wong ST, Zhang XQ, Zhuang JT, Chan HL, Li CH, Leung GK. MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Anticancer Res 2012; 32:2835-41; PMID:22753745
62. Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, Wang Z, Philip PA, Sarkar FH. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010; 70:3606-17; PMID:20388782; http://dx.doi.org/10.1158/0008-5472.CAN-09-4598
63. Noonan EM, Shah D, Yaffe MB, Lauffenburger DA, Samson LD. O6-Methylguanine DNA lesions induce an intra-S-phase arrest from which cells exit into apoptosis governed by early and late multi-pathway signaling network activation. Integr Biol (Camb) 2012; 4:1237-55; PMID:22892544; http://dx.doi.org/10.1039/c2ib20091k
64. Roos WP, Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett 2013; 332:237-48; PMID:22261329; http://dx.doi.org/10.1016/j.canlet.2012.01.007
65. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S, Pineau P, Marchio A, Palatini J, Suh SS, et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 2011; 208:875-83; PMID:21518799; http://dx.doi.org/10.1084/jem.20110235
66. Ouafik L, Berenguer-Daize C, Berthois Y. Adrenomedullin promotes cell cycle transit and up-regulates cyclin D1 protein level in human glioblastoma cells through the activation of c-Jun/JNK/AP-1 signal transduction pathway. Cell Signal 2009; 21:597-608; PMID:19166930; http://dx.doi.org/10.1016/j.cellsig. 2009.01.001
67. Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006; 8:209-17; PMID:16645207; http://dx.doi.org/10.2353/jmoldx.2006.050135 (Pubitemid 43811244)
68. Widschwendter M, Siegmund KD, Müller HM, Fiegl H, Marth C, Müller-Holzner E, Jones PA, Laird PW. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004; 64:3807-13; PMID:15172987; http://dx.doi.org/10.1158/0008-5472. CAN-03-3852 (Pubitemid 38697289)